IOVAIovance Biotherapeutics, Inc.
$14.61+613% 1Y
$14.61
$1.8152 weeks$14.79
IOVA in its own filings
IOVA's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
428
Events found in the filings · across 1,042 filings · the record starts in 2008
- Hard flags
- 3
Hard flags
- Most recent filing
- Oct 5, 2026
Most recent filing · Form 8-K
- Record starts
- Feb 20, 2008
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountant6 occurrences
- 2021-03-12
- Late periodic report11 occurrences
- 2013-08-15
- Delisting notice / listing-rule failurehistorical
- 2012-03-06
- SEC comment-letter activity48 occurrences
- 2023-11-21
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026On October 5, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Other event · Form 8-K
- Sep 29, 2026On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance.Other event · Form 8-K
- Aug 6, 2026On August 6, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Other event · Form 8-K
- Aug 6, 2026Biotherapeutics Reports Record Second Quarter 2026.Earnings release · press release
- Jul 2, 2026On June 30, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Other event · Form 8-K
- Jun 10, 2026On June 4, 2026, the Company received marketing authorization from the Therapeutic Goods Administration of Australia for Amtagvi® for previously treated advanced (metastatic or unresectable) melanoma.Shareholder vote results · Form 8-K
- May 7, 2026Iovance Biotherapeutics Highlights Positive.Earnings release · press release
- Mar 20, 2026On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the “Board”) of Iovance Biotherapeutics, Inc. (the “Company”), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company’s annual meeting of stockholders (the “Annual Meeting”) currently …Director or officer change · Form 8-K
- Feb 24, 2026On February 24, 2026, the Company updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Earnings release · Form 8-K
- Jan 9, 2026On January 9, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Other event · Form 8-K
- Nov 6, 2025Iovance Biotherapeutics Highlights Business.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks